Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Melanoma 2Carcinosarcoma 2Bile Duct Neoplasms 2Advanced Solid Tumours 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour Refractory to Conventional Treatment 1Salivary Gland Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1

Interventions

adavosertib 5durvalumab 3Paclitaxel 3olaparib 2ceralasertib 2Fluorouracil 2Carboplatin 2toripalimab 1sintilimab 1pembrolizumab 1factor IX, factor VII, factor X, prothrombin drug combination 1drug XX Z 1danvatirsen 1capivasertib 1Rifampin 1Pantoprazole 1Omeprazole 1Leucovorin 1Itraconazole 1Irinotecan 1Injections 1Gemcitabine 1Doxorubicin 1Cisplatin 1AZD0156 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumours × ceralasertib × Clear all
NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
14 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT06929260 2026-01-22

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

AstraZeneca

Phase 1 Terminated
1 enrolled
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡